EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BRD2 bromodomain-mediated regulation of cell state plasticity modulates therapy response in glioblastoma

Raghavendra Vadla iD, Brett Taylor, Yohei Miyake, Benjamin Lin, Daisuke Kawauchi, Shunichiro Miki, Nidhi Nathwani, Brandon M Jones, Yashpreet Kaur, Abhinaba Banerjee, Philip Pham, Jonathan Tsang und 5 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Raghavendra Vadla und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Regenerative Medicine, Department of Medicine, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Protein Serine-Threonine Kinases, Cell Plasticity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) displays remarkable cell state plasticity, a major contributor to therapeutic resistance and tumor progression. While epigenetic mechanisms play a central role in driving this plasticity, the key regulators remain poorly understood, and developing effective therapeutic strategies targeting them has been challenging.

Methods

We investigated the role of BRD2, a key regulator of NF-κB-mediated mesenchymal (MES) transition, using GBM patient-derived xenograft cell lines, CRISPR-mediated knock-in/knockout approaches, RNA-seq, and in vitro and in vivo modeling. BET inhibitors were employed to target MES gene expression and sensitize GBM to radiation therapy.

Results

We found that PTEN loss induces RelA chromatin localization and acetylation-mediated recruitment of BRD2 to the MES gene promoters. BRD2 binding is essential for maintaining MES gene expression and phenotype. Genetic ablation or loss-of-function mutation of BRD2 bromodomains reverses MES transition, enhances radiation sensitivity, and improves survival in orthotopic xenograft models. Additionally, treatment with a brain-penetrant BD2-selective inhibitor suppresses the MES phenotype and increases radiation sensitivity of GBM stem cells in vitro.

Conclusion

Our study identifies BRD2 as a key mediator of MES transition in GBM, with its bromodomains playing a crucial role in driving cell state plasticity. Targeting BRD2 with BD2-selective inhibitors offers a promising therapeutic strategy to overcome radiation resistance and improve outcomes for GBM patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsProtein Serine-Threonine KinasesCell PlasticityHumansAnimalsMiceXenograft Model Antitumor AssaysGene Expression Regulation, NeoplasticTumor Cells, CulturedRadiation ToleranceCell Line, TumorBromodomain Containing ProteinsTranscription Factors

Stichwörter der Autor:innen

BET inhibitorsBRD2NF-κB signalingglioblastomamesenchymal

Substanzen

BRD2 protein, humanProtein Serine-Threonine KinasesBromodomain Containing ProteinsTranscription Factors

Autor:innen und Institutionen

  • Division of Regenerative Medicine, Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Medical Scientist Training Program, University of California, San Diego, La Jolla, California, USA.
  • Medical Scientist Training Program, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Department of Bioengineering, University of California, San Diego, La Jolla, California, USA.
  • Departments of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA.

ORCID-Profile: Raghavendra Vadla, Frank B Furnari

Förderung

  • NIH HHS
  • NCI NIH HHS
  • NINDS NIH HHS
  • NIH

Zitieren

APA

Vadla, R., Taylor, B., Miyake, Y., Lin, B., Kawauchi, D., Miki, S., Nathwani, N., Jones, B. M., Kaur, Y., Banerjee, A., Pham, P., Tsang, J., Baldwin, A., Nathanson, D. A., Pizzo, D. P., Miller, C. R., & Furnari, F. B. (2025). BRD2 bromodomain-mediated regulation of cell state plasticity modulates therapy response in glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf169

Vancouver

Vadla R, Taylor B, Miyake Y, Lin B, Kawauchi D, Miki S, et al. BRD2 bromodomain-mediated regulation of cell state plasticity modulates therapy response in glioblastoma. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf169

BibTeX
@article{Vadla2025,
  author = {Vadla, Raghavendra and Taylor, Brett and Miyake, Yohei and Lin, Benjamin and Kawauchi, Daisuke and Miki, Shunichiro and Nathwani, Nidhi and Jones, Brandon M and Kaur, Yashpreet and Banerjee, Abhinaba and Pham, Philip and Tsang, Jonathan and Baldwin, Albert and Nathanson, David A and Pizzo, Donald P and Miller, C Ryan and Furnari, Frank B},
  title = {BRD2 bromodomain-mediated regulation of cell state plasticity modulates therapy response in glioblastoma},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf169}
}
Kostenlos starten →